+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proteomic and genomic biomarkers for age-related macular degeneration



Proteomic and genomic biomarkers for age-related macular degeneration



Advances in Experimental Medicine and Biology 664: 411-417



Toward early detection of susceptibility to age-related macular degeneration (AMD), we quantified plasma carboxyethylpyrrole (CEP) oxidative protein modifications and CEP autoantibodies by ELISA in 916 AMD and 488 control donors. Mean CEP adduct and autoantibody levels were elevated in AMD plasma by ∼60 and ∼30%, respectively, and the odds ratio for both CEP markers elevated was ∼3-fold greater in AMD than in control patients. Genotyping was performed for AMD risk polymorphisms associated with age-related maculopathy susceptibility 2 (ARMS2), high-temperature requirement factor A1 (HTRA1), complement factor H (CFH), and complement C3. The AMD risk predicted for those exhibiting elevated CEP markers and risk genotypes was 2- to 3-fold greater than the risk based on genotype alone. AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers. Receiver operating characteristic curves suggest that CEP markers alone can discriminate between AMD and control plasma donors with ∼76% accuracy and in combination with genomic markers, provide up to ∼80% discrimination accuracy. CEP plasma biomarkers, particularly in combination with genomic markers, offer a potential early warning system for predicting susceptibility to this blinding disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055256859

Download citation: RISBibTeXText

PMID: 20238042


Related references

Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Molecular and Cellular Proteomics 8(6): 1338-1349, 2009

Proteomic Profiles in Advanced Age-Related Macular Degeneration Using an Aptamer-Based Proteomic Technology. Translational Vision Science and Technology 8(1): 14, 2019

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). Ophthalmology 124(3): E31-E32, 2017

Proteomic Approaches to Age-Related Macular Degeneration. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 860, 2002

Proteomic approaches to understanding age-related macular degeneration. Advances in Experimental Medicine and Biology 533: 83-89, 2003

Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. Retina 27(7): 879-890, 2007

Proteomic analysis of the aqueous humor in patients with wet age-related macular degeneration. Proteomics. Clinical Applications 7(7-8): 550-560, 2013

Proteomic analysis of the aqueous humor in age-related macular degeneration (AMD) patients. Journal of Proteome Research 11(8): 4034-4043, 2012

Genomic aspects of age-related macular degeneration. Biochemical and Biophysical Research Communications 452(2): 263-275, 2014

Genetic markers and biomarkers for age-related macular degeneration. Expert Review of Ophthalmology 2(3): 443-457, 2007

Identification of urinary biomarkers for age-related macular degeneration. Investigative Ophthalmology and Visual Science 52(7): 4639-4644, 2011

Serum cytokines as biomarkers for age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 253(5): 699-704, 2015

Risk factors and biomarkers of age-related macular degeneration. Progress in Retinal and Eye Research 54: 64, 2016

Carboxyethylpyrrole plasma biomarkers in age-related macular degeneration. Drugs of the Future 36(9): 712-718, 2011

Comparative proteomic analysis of plasma proteins in patients with age-related macular degeneration. International Journal of Ophthalmology 7(2): 256-263, 2014